UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004627
Receipt number R000005521
Scientific Title Extended Treatment with Statin on Atheroma Regression Evaluated by Intravascular Ultrasound with Virtual Histology (Extended TRUTH Study)
Date of disclosure of the study information 2010/11/26
Last modified on 2012/08/21 11:24:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Extended Treatment with Statin on Atheroma Regression Evaluated by Intravascular Ultrasound with Virtual Histology (Extended TRUTH Study)

Acronym

Extended TRUTH Study

Scientific Title

Extended Treatment with Statin on Atheroma Regression Evaluated by Intravascular Ultrasound with Virtual Histology (Extended TRUTH Study)

Scientific Title:Acronym

Extended TRUTH Study

Region

Japan


Condition

Condition

Patients with stable angina or unstable angina

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Among the subjects registered for the TRUTH Study, there were some patients for whom baseline and follow-up measurements of coronary artery plaque (obtained using VH-IVUS) were available. The effects of long-term lipid-lowering therapy with pitavastatin or pravastatin on changes in plaque will be investigated in these patients. Moreover, correlation between change in plaque composition and cardiovascular events will be evaluated. In addition, we will evaluate the impacts of serum markers or different type of statins on cardiovascular events.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in component of coronary artery plaque measured by VH-IVUS

Key secondary outcomes

1)Vessel volume, Lumen volume, Plaque volume
2)Cardiovascular composite events (cardiovascular death, nonfatal myocardial infarction, nonfatal cerebral infarction, unstable angina, revascularization except target lesion revascularization)
3)change of serum lipid (TC, LDL-C, TG, HDL-C)
4)others marker (hs-CRP)


Base

Study type

Interventional


Study design

Basic design

expanded access

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

pitavastain group

Interventions/Control_2

pravastatin group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Among subjects registered for the TRUTH Study, patients (FAS subjects) available for baseline and follow-up measurement of coronary artery plaque using VH-IVUS gave consent to participate in this research

Key exclusion criteria

1)Patients meeting the contraindications or relative contraindications for pitavastatin and pravastatin
2)Patients with hepatic disorder or with AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limits of normal
3)Patients with renal dysfunction(serum creatinine 2.0mg/dL or higher)
4)Patients with a history of severe muscular disorder or with CK(CPK) greater than 2.5 times of the upper limit of normal
5)Patients with acute myocardial infarction occurred within 24 hours
6)Patients having failed to PCI
7)Patients with cerebrovascular accident occurred within 1 month
8)Patients with concurrent or a history of malignant tumor within 5 years prior to start of the investigationak drug
9)Patients receiving LDL apheresis
10)Patients with homozygous familial hypercholesterolemia
11)Patients requiring the following prohibited concomitant drugs
12)Drug abusers
13)Patients participating in other studies
14)Patients ineligible for the study determined by doctors

Target sample size

119


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ichiro Michishita

Organization

Yokohama Sakae Kyosai Hospital

Division name

Division of Cardiology, Department of Internal Medicine

Zip code


Address

132 Katsuta-cho, Sakae-ku, Yokohama, 247-8581, Japan

TEL

045-891-2171

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kanagawa PTCA Conference

Division name

Office

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Kanagawa PTCA Conference

Institute

Department

Personal name



Funding Source

Organization

Japan Heart Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 11 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 04 Month 22 Day

Date of IRB


Anticipated trial start date

2010 Year 07 Month 01 Day

Last follow-up date

2011 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 11 Month 26 Day

Last modified on

2012 Year 08 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005521


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name